BioSpace News Archive

Wearables have become another weapon to track, monitor, and fight the progression of COVID-19 and its symptoms worldwide.

Patients will be assessed in advance of enrollment to ensure safety, due to COVID-19 pandemic

Obalon reported no device-related serious adverse events (0%) for first 141 patients completing therapy in post-approval study to FDA

As April and National Occupational Therapy Month come to a close, The University of St. Augustine for Health Sciences wants to recognize the unique ways Occupational Therapists are helping people during the COVID-19 Pandemic.

Denovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it is acquiring Tocagen’s retroviral replicating vector platform (RRV) in its entirety, including its investigational gene therapy and drug regimen for oncology: Toca 511 and Toca FC (now known as DB107), and several early-stag

Vonco Products LLC, an industry leader in contract manufacturing of liquid-tight medical fluid bags and components for custom medical device applications, has positioned itself as a vital contributor in the fight against COVID-19 as the company pivots to produce desperately needed Personal Protective Equipment in addition to its existing lineup of infection prevention products.

Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases, today announced the pricing of an underwritten public offering of 11,652,830 shares of its common stock at a price to the public of $4.75 per share. In addition, and in lieu of common stock, Aeglea is offering to certain investors pre-funded warra

Sales Rep Training, Forecasting, Competitive Intelligence, Patient Support Services, and KOL Relationship Management among the Functions within the Pharmaceutical Commercial Model Most in Need of Change During and Post-Pandemic

Individuals can purchase COVID-19 antibody testing for themselves online, without visiting a doctor’s office, through QuestDirect, the consumer-initiated testing business of Quest Diagnostics, the world’s leading provider of diagnostic information services.

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it will report its financial results for the first quarter ended March 31, 2020, after the market close and host a corporate update conference call and webcast on Tuesday, May 12, at 4:30 p.m. Eastern Time. Conference Call Details: Tuesday, May 12 th at 4:30